Story perspectives

UK Gene Therapies Struggle Amid High Costs, Funding Gaps

12/22/2025

24 3

Summary

Story summary

The United Kingdom's gene therapies for rare diseases face development and funding hurdles as costs reach six figures.
Those costs drive a shift in business models, with incentives favoring profitable drugs.
Some argue from a left-leaning perspective that the National Health Service (NHS) should provide these treatments as a service, instead of market goods.
Biotech research has shifted to the United States and China, complicating Britain's position in medical innovation.

1 of 1

Story summary

The United Kingdom's gene therapies for rare diseases face development and funding hurdles as costs reach six figures.
Those costs drive a shift in business models, with incentives favoring profitable drugs.
Some argue from a left-leaning perspective that the National Health Service (NHS) should provide these treatments as a service, instead of market goods.
Biotech research has shifted to the United States and China, complicating Britain's position in medical innovation.